High-rolling investors have positioned themselves bullish on Pfizer PFE, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in PFE often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 11 options trades for Pfizer. This is not a typical pattern.
The sentiment among these major traders is split, with 63% bullish and 36% bearish. Among all the options we identified, there was one put, amounting to $27,840, and 10 calls, totaling $419,677.
Projected Price Targets
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $22.5 and $32.5 for Pfizer, spanning the last three months.
Volume & Open Interest Development
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Pfizer's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Pfizer's whale trades within a strike price range from $22.5 to $32.5 in the last 30 days.
Pfizer 30-Day Option Volume & Interest Snapshot
Largest Options Trades Observed:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|
| PFE | CALL | SWEEP | BULLISH | 02/16/24 | $30.00 | $66.8K | 23.4K | 662 |
| PFE | CALL | TRADE | BULLISH | 01/17/25 | $32.50 | $49.4K | 19.6K | 382 |
| PFE | CALL | SWEEP | BULLISH | 02/16/24 | $30.00 | $45.3K | 23.4K | 3.7K |
| PFE | CALL | SWEEP | BULLISH | 01/05/24 | $28.50 | $41.1K | 3.7K | 73 |
| PFE | CALL | SWEEP | BEARISH | 06/21/24 | $29.00 | $38.6K | 2.0K | 99 |
About Pfizer
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
Where Is Pfizer Standing Right Now?
- Trading volume stands at 7,831,702, with PFE's price up by 0.62%, positioned at $28.59.
- RSI indicators show the stock to be is currently neutral between overbought and oversold.
- Earnings announcement expected in 34 days.
Professional Analyst Ratings for Pfizer
In the last month, 4 experts released ratings on this stock with an average target price of $33.25.
- Maintaining their stance, an analyst from UBS continues to hold a Neutral rating for Pfizer, targeting a price of $27.
- An analyst from Truist Securities has revised its rating downward to Buy, adjusting the price target to $42.
- Consistent in their evaluation, an analyst from Truist Securities keeps a Buy rating on Pfizer with a target price of $36.
- Maintaining their stance, an analyst from Barclays continues to hold a Equal-Weight rating for Pfizer, targeting a price of $28.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Pfizer options trades with real-time alerts from Benzinga Pro.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
